Biogen in the news
Biotech medicines global pioneering
Tamtam found 20 recent articles about Biogen.
- Biogen: Why I'm Still Bullish Despite Market Turmoil (NASDAQ:BIIB)
Biogen's shares are in an uptrend, driven by strong sales of Leqembi for Alzheimer's disease, leading to increased earnings guidance.
- Biogen (BIIB) PT Raised to $271 at Mizuho
Mizuho raised Biogen's price target to $271 due to anticipated strong commercial execution and upcoming Phase 3 trial results for key drugs like litifilimab.
- H.C. Wainwright reiterates Buy rating on Biogen stock at $270
H.C. Wainwright reaffirmed a Buy rating for Biogen, setting a $270 price target, following positive Phase 2 CELIA study data for diranersen and strong Q3 2026 financial results.
- Eisai and Biogen Present Clarity AD Analysis Showing Lecanemab Slows Decline in Early Alzheimer’s Disease Patients With α-Synuclein Co-Pathology
Eisai and Biogen's lecanemab slowed clinical decline in early Alzheimer's disease patients with α-synuclein co-pathology, according to a Clarity AD analysis presented at CTAD.
- Biogen unblurs life with Friedreich ataxia in patient-centered Skyclarys campaign
Biogen's Skyclarys campaign for Friedreich ataxia visually highlights patients' daily lives and passions, promoting the drug's role in slowing disease progression and emphasizing patient-centric care.
- Can Biogen (NASDAQ:BIIB) Strengthen Lecanemab Case With Biomarker Data?
Biogen and Eisai released new biomarker data from a lecanemab substudy, aiming to boost physician confidence and adoption for their Alzheimer's treatment.
- Biogen says low dose of its experimental tau-reducing drug fares even better after nearly 2 years
Biogen's experimental Alzheimer's drug, a tau-reducer, shows increasingly positive results with its lowest dose over nearly two years.
- Eisai and Biogen Report Three-Year Real-World LEQEMBI Data Showing Slower Alzheimer’s Progression in LEADER Study
LEQEMBI significantly slows the progression of early Alzheimer's disease, with 81.1% of patients remaining stable or improving, and 77% achieving amyloid clearance over an 18-month treatment period in a real-world study.
- Biogen to Participate in December Healthcare Conferences
Biogen executives will present at two healthcare conferences in late 2026, with webcasts available online.
- NICE initial recommendation not to approve tofersen
The National Institute for Health and Care Excellence (NICE) has initially declined to approve Biogen's drug, tofersen, for routine use on the NHS, citing a lack of sufficient data.
- Biogen reports two-year data for Alzheimer's drug diranersen
Biogen reported positive two-year results for its Alzheimer's drug diranersen, showing a 38% slowdown in clinical decline for the 60 mg dose.
- Biogen: 3 Key Takeaways for Long-Term Investors
Biogen's Q3 2026 earnings show strong growth driven by strategic acquisitions, successful product conversions, and an expanding pipeline.
- Biogen (BIIB) Reports Promising Phase 2 CELIA Trial Results for Early Alzheimer's Therapy
Biogen's experimental Alzheimer's drug, diranersen, showed promising Phase 2 trial results, but its stock is considered overvalued by 22.1%.
- Diranersen shows 38% clinical decline slowing a...
Biogen's stock is trading near its 52-week high on Pluang with strong investor buying despite a minor daily dip.
- Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Biogen is preparing to announce Phase 3 lupus trial results in early December and aims for its first revenue growth since 2019 next year.
- Biogen’s Diranersen Data Show Slower Alzheimer’s Decline Over Two Years
Biogen's diranersen shows slower Alzheimer's decline and 38% clinical benefit with 60 mg twice-yearly.
- Biogen reports positive two-year data for Alzheimer’s drug By Investing.com
Biogen announced positive two-year Phase 2 data for its experimental Alzheimer's drug, diranersen, which significantly slowed clinical decline.
- Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
Biogen's anti-tau Alzheimer's drug demonstrates enhanced benefits after two years.
- Biogen releases new mid-stage data for early Alzheimer's asset diranersen
Biogen's diranersen for early Alzheimer's disease slowed clinical decline by 38% over two years in Phase 2.
- The Rosen Law Firm, P.A. Announces Proposed Class Action
A proposed class action settlement for purchasers of Biogen common stock, totaling $25 million, is pending court approval with a fairness hearing scheduled for March 5, 2027.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Biogen?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies